Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)

Amand F. Schmidt; Michael H. Davidson; Marc Ditmarsch; John J. Kastelein; Chris Finan

doi:10.1186/s13195-024-01639-w

Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)

Amand F. Schmidt^*
, Michael H. Davidson
, Marc Ditmarsch
, John J. Kastelein
, Chris Finan

^*Corresponding author for this work

Department of Cardiology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

6 Downloads (Pure)

Abstract

Correction: Alz Res Therapy 16, 228 (2024) Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section. The current wording erroneously states that CETP inhibitors decreases Apo-E concentration: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer’s disease (AD). Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD). The original article [1] has been updated.

Original language	English
Article number	276
Journal	Alzheimer's Research and Therapy
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s13195-024-01639-w
Publication status	Published - 27 Dec 2024

Access to Document

10.1186/s13195-024-01639-wLicence: CC BY

s13195-024-01639-wFinal published version, 632 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)'. Together they form a unique fingerprint.

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis
Schmidt, A. F., Davidson, M. H., Ditmarsch, M., Kastelein, J. J. & Finan, C., 16 Oct 2024, In: Alzheimer's Research and Therapy. 16, 1, 9 p., 228.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
1 Downloads (Pure)

Cite this

Schmidt, A. F., Davidson, M. H., Ditmarsch, M., Kastelein, J. J., & Finan, C. (2024). Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6). Alzheimer's Research and Therapy, 16(1), Article 276. https://doi.org/10.1186/s13195-024-01639-w

@article{b29fa931e3fd4ca9ac3f5e8117d82c51,

title = "Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research \& Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)",

abstract = "Correction: Alz Res Therapy 16, 228 (2024) Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section. The current wording erroneously states that CETP inhibitors decreases Apo-E concentration: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer{\textquoteright}s disease (AD). Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer{\textquoteright}s disease (AD). The original article [1] has been updated.",

author = "Schmidt, \{Amand F.\} and Davidson, \{Michael H.\} and Marc Ditmarsch and Kastelein, \{John J.\} and Chris Finan",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "27",

doi = "10.1186/s13195-024-01639-w",

language = "English",

volume = "16",

journal = "Alzheimer's Research and Therapy",

issn = "1758-9193",

publisher = "BioMed Central Ltd.",

number = "1",

}

Schmidt, AF, Davidson, MH, Ditmarsch, M, Kastelein, JJ & Finan, C 2024, 'Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)', Alzheimer's Research and Therapy, vol. 16, no. 1, 276. https://doi.org/10.1186/s13195-024-01639-w

Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6). / Schmidt, Amand F.; Davidson, Michael H.; Ditmarsch, Marc et al.
In: Alzheimer's Research and Therapy, Vol. 16, No. 1, 276, 27.12.2024.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Correction to

T2 - Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)

AU - Schmidt, Amand F.

AU - Davidson, Michael H.

AU - Ditmarsch, Marc

AU - Kastelein, John J.

AU - Finan, Chris

PY - 2024/12/27

Y1 - 2024/12/27

N2 - Correction: Alz Res Therapy 16, 228 (2024) Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section. The current wording erroneously states that CETP inhibitors decreases Apo-E concentration: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer’s disease (AD). Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD). The original article [1] has been updated.

AB - Correction: Alz Res Therapy 16, 228 (2024) Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section. The current wording erroneously states that CETP inhibitors decreases Apo-E concentration: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer’s disease (AD). Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD). The original article [1] has been updated.

UR - https://www.scopus.com/pages/publications/85213266166

U2 - 10.1186/s13195-024-01639-w

DO - 10.1186/s13195-024-01639-w

M3 - Comment/Letter to the editor

AN - SCOPUS:85213266166

SN - 1758-9193

VL - 16

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

IS - 1

M1 - 276

ER -

Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)

Abstract

Access to Document

Other files and links

Fingerprint

Research output

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis

Cite this